Search hospitals > Kentucky > Lexington
Albert B. Chandler Medical Center, University of Kentucky
Claim this profileLexington, Kentucky 40508
Global Leader in Lung Cancer
Global Leader in Ovarian Cancer
Conducts research for Leukemia
Conducts research for Neck Cancer
Conducts research for Head and Neck Cancers
241 reported clinical trials
7 medical researchers
Summary
Albert B. Chandler Medical Center, University of Kentucky is a medical facility located in Lexington, Kentucky. This center is recognized for care of Lung Cancer, Ovarian Cancer, Leukemia, Neck Cancer, Head and Neck Cancers and other specialties. Albert B. Chandler Medical Center, University of Kentucky is involved with conducting 241 clinical trials across 278 conditions. There are 7 research doctors associated with this hospital, such as Daniel Lee, MD, Francis Farhadi, MD, PhD, Frederick R. Ueland, and Sharoon Qaiser.Area of expertise
1Lung Cancer
Global LeaderStage IV
Stage III
PD-L1 positive
2Ovarian Cancer
Global LeaderStage III
Stage IV
BRCA
Top PIs
Daniel Lee, MDWills Eye Hospital6 years of reported clinical research
Studies Glaucoma
Studies Open-Angle Glaucoma
10 reported clinical trials
18 drugs studied
Francis Farhadi, MD, PhDUniversity of Kentucky1 year of reported clinical research
Studies Spinal Cord Injury
Studies Lower Back Pain
6 reported clinical trials
9 drugs studied
Frederick R. UelandUniversity of Kentucky/Markey Cancer Center9 years of reported clinical research
Studies Ovarian Cancer
Studies Endometrial Cancer
5 reported clinical trials
11 drugs studied
Sharoon QaiserUniversity of Kentucky Chandler Medical Center5 years of reported clinical research
Studies Migraine
Studies Vestibular Migraine
4 reported clinical trials
3 drugs studied
Clinical Trials running at Albert B. Chandler Medical Center, University of Kentucky
Lung Cancer
Prostate Cancer
Migraine
Cancer
Spinal Cord Injury
Stroke
Ovarian Cancer
Non-Small Cell Lung Cancer
Multiple Sclerosis
Sleep Apnea
LY3537982 + Immunotherapy/Chemotherapy
for Non-Small Cell Lung Cancer
This trial is testing a new drug, LY3537982, combined with standard treatments for patients with advanced lung cancer that have a specific genetic mutation. The goal is to see if this combination works better than the usual treatments alone.
Recruiting1 award Phase 314 criteria
BNT116 + Standard Therapy
for Non-Small Cell Lung Cancer
This first-in-human (FIH) trial for BNT116 aims to establish the safety profile and a safe dose for BNT116 monotherapy as well as for BNT116 in combination with approved medicinal products and/or in combination with investigational medicinal products (IMPs) including, but not limited to, cemiplimab, docetaxel, carboplatin, paclitaxel, BNT316 (an anti-cytotoxic T-lymphocyte-associated protein 4 \[CTLA-4\] antibody), an anti-B7-H3 antibody conjugated to a topoisomerase I inhibitor, an anti-human epidermal growth factor receptor 3 (HER3) antibody conjugated to a topoisomerase I inhibitor or a bispecific antibody for programmed death ligand 1 (PD-L1) and vascular endothelial growth factor A (VEGF-A) in participants with non-small cell lung cancer (NSCLC). The trial will comprise of several cohorts for dose confirmation in monotherapy as well as in combinations of BNT116 as mentioned above. The trial will enroll participants with NSCLC in advanced or metastatic stage in Cohorts 1 to 4 and Cohorts 7 to 10, unresectable NSCLC Stage III in Cohorts 5 and 11, and resectable NSCLC of Stage II and III in Cohort 6.
Recruiting1 award Phase 115 criteria
Investigational Agents
for Lung Cancer
Researchers are looking for other ways to treat metastatic squamous non-small cell lung cancer (NSCLC). Squamous NSCLC is cancer that starts in squamous cells, which are flat cells that line the inside of the airways in the lungs. Metastatic means the cancer has spread to other parts of the body. Standard treatment (usual treatment) for metastatic squamous NSCLC is immunotherapy with or without chemotherapy. Immunotherapy is a treatment that helps the immune system fight cancer. Chemotherapy is medicine that destroys cancer cells or stops them from growing. However, standard treatment may not work or may stop working to treat metastatic squamous NSCLC. Researchers want to learn if study treatments that are antibody drug conjugates (ADCs) can treat metastatic squamous NSCLC that did not respond (get smaller or go away) to standard treatment. An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The main goals of this study are to learn about: * The cancer response to the study treatments compared to chemotherapy * The safety of the study treatments and if people tolerate them This study is one of the substudies being conducted under one pembrolizumab umbrella master protocol (MK-3475-U01/KEYMAKER-U01).
Recruiting1 award Phase 23 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Albert B. Chandler Medical Center, University of Kentucky?
Albert B. Chandler Medical Center, University of Kentucky is a medical facility located in Lexington, Kentucky. This center is recognized for care of Lung Cancer, Ovarian Cancer, Leukemia, Neck Cancer, Head and Neck Cancers and other specialties. Albert B. Chandler Medical Center, University of Kentucky is involved with conducting 241 clinical trials across 278 conditions. There are 7 research doctors associated with this hospital, such as Daniel Lee, MD, Francis Farhadi, MD, PhD, Frederick R. Ueland, and Sharoon Qaiser.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.